Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01073319 · ClinicalTrials.gov registry record · Phase 1
Rivastigmine as a Treatment for Methamphetamine Dependence
A Phase 1 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01073319: Completed Phase 1 study, sponsored by Baylor College of Medicine.
NCT01073319 is a Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01073319, a Phase 1 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
To study the effects of treatment with rivastigmine on craving produced by experimental administration of methamphetamine.
Primary Outcome
Beginning with intake, vital signs (temperature with orthostatic BP and HR) will be recorded every 8 hours. Before and after the intravenous METH infusion, subjects' physiologic responses will be closely monitored using repeated HR, BP, and ECG readings.
Interventions
- OTHER Placebo
- DRUG Rivastigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
What the finished NCT01073319 record still lists
NCT01073319 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01073319 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01073319 about?
NCT01073319 is a clinical study titled "Rivastigmine as a Treatment for Methamphetamine Dependence". To study the effects of treatment with rivastigmine on craving produced by experimental administration of methamphetamine.
What is the current status of trial NCT01073319?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2009-07. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01073319?
The interventions under investigation include: Placebo (OTHER), Rivastigmine (DRUG).
Who is sponsoring clinical trial NCT01073319?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01073319's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia